2,914 material Form 8-K filings that 2,352 companies we cover made with the SEC in August 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Tyson Foods agreed to sell $1.0 billion of senior notes in two $500 million tranches, a 5.100% series due 2031 and a 5.600% series due 2037, under an underwriting agreement dated August 10, 2026. The company plans to use the net proceeds to purchase notes tendered in a contemplated tender offer, with any remainder used for general corporate purposes. The offering is expected to close on August 24, 2026, subject to customary closing conditions.
Two $500 million tranches: 5.100% senior notes due 2031 and 5.600% senior notes due 2037
Underwriters include BofA Securities, J.P. Morgan, Morgan Stanley and Rabo Securities as representatives
Expected closing date is August 24, 2026
Net proceeds are intended for a contemplated tender offer, with any remainder for general corporate purposes
On August 4, 2026, Olenox Industries amended its May 29, 2025 Stock Purchase Agreement and Registration Rights Agreement with General Alpha Ltd. The amendment lets the purchaser deduct up to 30% of a Put amount to pay outstanding principal or interest on notes it holds, removes the True-Up and Review of Public Disclosures sections, narrows anti-dilution protection, and extends the purchase agreement's expiration to August 3, 2028. The changes alter terms governing the company's equity financing with this investor, which bears on shareholder dilution and protections.
Amendment dated August 4, 2026 changes the May 29, 2025 Stock Purchase Agreement and Registration Rights Agreement with General Alpha Ltd.
Purchase Agreement expiration date moved from May 8, 2026 to August 3, 2028.
Purchaser may deduct up to 30% of the Put amount to pay principal or interest on notes or convertible notes owed to it.
Sections 7.5 True-Up and 6.10 Review of Public Disclosures removed; anti-dilution now excludes certain share issuances, including those to insiders and conversions of preferred stock.
On August 3, 2026, East West Ave Acquisition Corp., a blank check company, closed its initial public offering of 10,000,000 units at $10.00 per unit, generating $100,000,000 in gross proceeds, and sold 272,500 private units to its sponsors for $2,725,000. The filing says $100,500,000 was placed in a trust account with Equiniti Trust Company, LLC, which holds the funds until a business combination or redemption. The company has not commenced operations, and its auditor included a going concern paragraph, meaning substantial doubt about its ability to continue, tied to the deadline to complete a business combination.
10,000,000 units sold at $10.00 each for $100,000,000 gross proceeds; each unit has one common share and one right to exchange for one-fourth of a common share upon a business combination
272,500 private units sold to sponsors East West Avenue LLC and NFR Capital Limited for $2,725,000
$100,500,000 placed in trust account; $867,845 in cash held outside the trust as of August 3, 2026
Company has until August 3, 2027 to complete an initial business combination, extendable to November 3, 2027; auditor Fortune CPA, Inc. cited substantial doubt about going concern
On August 10, 2026, MPT's operating partnership closed a private placement and private exchange issuing $2.4 billion of 9.25% senior secured notes due February 15, 2032. The company said proceeds will fund the full redemption of its 2026 senior notes and a partial redemption of its 2027 senior notes, and the exchange refinanced about $1.5 billion of unsecured notes maturing from 2027 to 2031.
$2.4 billion aggregate principal of 9.25% senior secured notes due February 15, 2032, issued August 10, 2026
Proceeds to fully redeem 2026 senior notes and partly redeem 2027 senior notes; private exchange refinanced about $1.5 billion of 2027–2031 unsecured notes
Interest paid semi-annually on June 15 and December 15, starting December 15, 2026; holders may require repurchase at 101% upon a change of control
Cogent Biosciences filed a prospectus supplement on August 10, 2026, covering the offer and sale of up to $400,000,000 of common stock through Guggenheim Securities under an existing sales agreement. The offering runs under an automatic shelf registration statement filed November 7, 2025, and the filing does not state a price or timing for any sales. For shareholders, this sets up a possible source of new shares that could dilute existing holdings if sold.
Up to $400,000,000 of common stock may be sold through Guggenheim Securities, as sales agent or principal, at market prices.
The prospectus supplement was filed August 10, 2026, under Form S-3ASR (File No. 333-291384).
Gibson, Dunn & Crutcher LLP issued a legal opinion on the shares (Exhibit 5.1).
GEN Restaurant Group entered a Sales Agreement with Roth Capital Partners on August 10, 2026, allowing it to sell up to $3,740,000 of Class A common stock through the agent over time. The company pays a 3.0% commission on gross proceeds and is not obligated to sell any shares, so the actual dilution to shareholders depends on how much it chooses to sell.
Maximum aggregate offering amount of up to $3,740,000 of Class A common stock through Roth Capital Partners, LLC
Agent commission of 3.0% of gross proceeds, plus certain agent expenses paid by the company
Proceeds intended for expanding the consumer packaged goods business, working capital, and general corporate purposes, which may include new restaurant openings
Shares sold under a Form S-3 shelf registration declared effective May 27, 2026, with a prospectus supplement dated August 10, 2026
HWH International Inc. closed a $10,000,000 private sale of 20,000,000 common shares and warrants for 160,000,000 more shares to Smart Dynamics Technology Limited on August 10, 2026, leaving the buyer with about 67.3% of outstanding stock. The filing names HWH International Inc., not EnerSyn Global Inc. (ESYN) as stated in the request, so the ticker and company name should be verified before publication. Shareholders face substantial dilution, the loss of the prior controlling holder's dominance, and anti-dilution limits on new equity sales for two years.
20,000,000 shares sold plus warrants for 160,000,000 shares at $0.63 per share, expiring August 10, 2030, for $10,000,000 total
Purchaser holds about 67.3% of outstanding shares; Chairman and CEO Heng Fai Chan's stake falls to 27% from 82.4% before closing
Board expands from five to eight seats, with Liu Chang, Liu Ming Xing and Liu Ming Hui appointed August 10, 2026
Company issued 2,000,000 stock awards on August 7, 2026, including 1,480,000 shares to Heng Fai Chan
On August 6, 2026, MasTec agreed to sell $650 million of 5.850% senior unsecured notes due September 30, 2036, priced at 99.656%. The company intends to use the net proceeds to repay some or all of its $600 million term loan maturing June 26, 2028, with closing expected on August 17, 2026, subject to customary conditions.
$650 million aggregate principal of 5.850% senior notes due September 30, 2036, priced at 99.656%
Interest payable semi-annually; closing expected August 17, 2026, subject to customary conditions
Net proceeds intended to repay some or all of a $600 million term loan maturing June 26, 2028, plus fees and expenses
Representatives of the underwriters are PNC Capital Markets LLC, Truist Securities, Inc. and Wells Fargo Securities, LLC
Pinnacle Acquisition Corporation, a blank check company, closed its initial public offering of 20,000,000 units at $10.00 per unit on August 6, 2026, for gross proceeds of $200,000,000. The full $200,000,000 was placed in a trust account, which can be released only on completing an initial business combination or on redemption if no combination is completed within 21 months of the IPO closing, so shareholder funds stay restricted until a deal or liquidation.
20,000,000 units sold at $10.00 each, for gross proceeds of $200,000,000; units began trading on the NYSE on August 7, 2026 under PNAQ.U
Sponsor PAC Sponsor, LLC bought 225,000 private placement units for $2,250,000 at closing
$200,000,000 placed in a trust account with Continental Stock Transfer & Trust Company; includes up to $6,000,000 of deferred underwriter discount and commissions
Andrew Rechtschaffen, Karen Martin, Paul Stoyan and Harry Brandler joined the board on August 6, 2026, alongside Steven K. Hudson
On August 10, 2026, Alphabet closed an underwritten public offering of $25 billion in U.S. dollar senior notes issued under an existing 2016 indenture with The Bank of New York Mellon Trust Company as trustee. The offering includes ten tranches, both floating rate and fixed rate, with maturities from 2028 to 2066. The filing does not state how Alphabet will use the proceeds.
Total principal amount of $25 billion across ten tranches
Fixed rate notes carry coupons from 4.500% (due 2028) to 6.500% (due 2066)
Largest tranches are $4.5 billion of 5.450% notes due 2036 and $4.5 billion of 6.375% notes due 2056
Issued under an indenture dated February 12, 2016, with The Bank of New York Mellon Trust Company, N.A., as trustee
CoreWeave's subsidiary CoreWeave Financing DDTL V-V, LLC entered into a credit agreement on August 7, 2026 for a $2.6 billion delayed draw term loan facility, which the company announced as closed on August 10, 2026. The facility was used primarily to finance capital expenditures for customer contracts, including GPU servers and related infrastructure, and the parent guarantees the obligations, which are secured by substantially all of the borrower's assets. The new debt adds a secured obligation with a debt service coverage covenant of at least 1.35x, which shareholders may want to weigh against the company's other borrowings.
Facility size is $2.6 billion, available in draws until the commitment termination date in December 2026
Maturity date is September 1, 2031; priced at Term SOFR plus a 5.50% margin, with a 0.50% annual undrawn fee
Parent CoreWeave, Inc. guarantees all obligations; debt service coverage ratio must be at least 1.35x starting after the earlier of full commitment reduction or December 31, 2026
Facility received Ba2 from Moody's and BB+ from Fitch, according to the press release
Teradyne entered a five-year, $1.0 billion senior secured revolving credit facility with PNC Bank, National Association, as administrative agent, on August 7, 2026. The company has not borrowed under the facility, which can fund working capital and general corporate purposes.
No borrowings made under the facility as of the filing
Financial covenants include a maximum consolidated leverage ratio of 3.50:1.00 (4.00:1.00 after an acquisition over $200 million) and a minimum interest coverage ratio of 2.50:1.00
Collateral and guarantees are released if the company reaches investment grade ratings from at least two of S&P, Moody's and Fitch
Skyworks Solutions issued $2.0 billion of senior notes in three tranches due 2028, 2032 and 2036, to help finance about $3.00 billion in cash consideration for its planned acquisition of Qorvo. The 2028 and 2036 notes carry a special mandatory redemption if the Qorvo merger is not completed, which shifts some financing risk back to the company if the deal fails.
Issued $800 million of 5.000% notes due 2028, $600 million of 5.750% notes due 2032 and $600 million of 6.250% notes due 2036
Proceeds, together with existing cash, are intended to fund about $3.00 billion in cash consideration for the Qorvo merger
2028 and 2036 notes must be redeemed early if the Qorvo merger does not close by 11:59 p.m. Pacific Time on November 3, 2027, or if the company abandons or the merger agreement is terminated
Notes were issued under an indenture with U.S. Bank Trust Company, National Association, as trustee
Latigo Biotherapeutics, Inc. closed its initial public offering on August 10, 2026, selling 19,200,000 shares of common stock at $18.00 per share. Gross proceeds were approximately $345.6 million before underwriting discounts, commissions and offering expenses. The company also filed an amended and restated certificate of incorporation and adopted amended and restated bylaws in connection with the closing.
IPO: 19,200,000 common shares sold at $18.00 per share on August 10, 2026
Gross proceeds of approximately $345.6 million, before underwriting discounts and expenses
Restated certificate of incorporation filed with the Delaware Secretary of State and restated bylaws adopted, both effective August 10, 2026
Full text of the restated documents filed as Exhibits 3.1 and 3.2
BlossomHill Therapeutics, Inc. closed its initial public offering on August 10, 2026, selling 9,375,000 shares of common stock at $16.00 per share. The company also adopted an amended and restated certificate of incorporation and amended and restated bylaws in connection with the closing. The filing gives gross proceeds before underwriting discounts and offering expenses, which are not yet deducted.
IPO of 9,375,000 shares of common stock at $16.00 per share, closed August 10, 2026
Approximate aggregate gross proceeds of $150.0 million, before underwriting discounts, commissions and estimated offering expenses
Amended and restated certificate of incorporation filed with Delaware Secretary of State; restated bylaws adopted effective August 10, 2026
Restated bylaws were previously filed as Exhibit 3.4 to Form S-1 (File No. 333-297512) on July 17, 2026
Medical Properties Trust reported a smaller second-quarter 2026 net loss than a year earlier, with total revenues and normalized FFO both higher. The company also announced a $2.4 billion private placement and exchange of 9.25% senior secured notes due 2032, which it says is expected to close imminently and will repay 2026 notes and about half of its 2027 notes.
Q2 2026 net loss of $3 million ($0.01 per share), compared with a net loss of $98 million ($0.16 per share) in Q2 2025
Normalized FFO of $92 million ($0.15 per share), up from $81 million ($0.14 per share) a year earlier
Total revenues of $259.3 million for Q2 2026, compared with $240.4 million in Q2 2025
$2.4 billion of new 9.25% senior secured notes due 2032; proceeds to repay 2026 notes and about 50% of 2027 notes
Replimune agreed on August 9, 2026 to sell 9,701,490 common shares and pre-funded warrants for 2,736,340 shares to underwriters at $12.06 per share. The company expects gross proceeds of about $150 million and net proceeds of about $140.5 million, with closing expected on August 11, 2026. Because the sale adds shares to those already outstanding, existing shareholders' ownership stake will be diluted.
Offering of 9,701,490 common shares at $12.06 per share, plus pre-funded warrants for 2,736,340 shares at $12.0599 per warrant
Expected gross proceeds of about $150 million; estimated net proceeds of about $140.5 million after underwriting discounts and offering expenses
Underwriters are Leerink Partners LLC, J.P. Morgan Securities LLC, and Cantor Fitzgerald & Co.; closing expected on or about August 11, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.